EUVIMEDEUVIMED entdecken
Crossref

Atrial fibrillation in chronic kidney disease - treatment standard

Caroline Schneppe, Gunnar H Heine, Ingo Eitel, Marie Evans iD, Lukas Urbanek, Wolfgang Winkelmayer iD, An S De Vriese iD

Nephrology Dialysis Transplantation · 13.11.2026

DOI: 10.1093/ndt/gfag263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 13.11.2026. Verfasst von Caroline Schneppe und 6 weiteren Autor:innen. Beteiligte Einrichtung: AGAPLESION MARKUS KRANKENHAUS, Department of Nephrology, Hypertension and Vascular Diseases, Frankfurt, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of atrial fibrillation (AF) is high among patients with chronic kidney disease (CKD). While patients with CKD Stages G1 – G3b may be treated similarly to patients without CKD, little evidence guides therapeutic strategies for CKD G4 - G5 patients. Dosing of most drugs used for rate and rhythm control requires adjustment to kidney function. Recurrence rates after cardioversion and ablation for rhythm control are higher in patients with advanced CKD than those without it. Regarding the prevention of stroke and systemic embolism, the benefit-to-risk ratio of oral anticoagulation (OAC) is disputed among patients with CKD stages G4 - G5 with AF, in particular among those receiving hemodialysis given their high risk for severe bleeding events. Novel strategies for stroke and systemic embolism prevention, particularly factor XI inhibitors and left atrial appendage occlusion (LAAO), have not yet fulfilled their initial promise as safe and effective alternatives.

Schlagwörter

Stichwörter der Autor:innen

CKDDOACLAAOanticoagulationatrial fibrillation

Autor:innen und Institutionen

  • AGAPLESION MARKUS KRANKENHAUS, Department of Nephrology, Hypertension and Vascular Diseases, Frankfurt, Germany.
  • Saarland University, Saarbrücken, Germany.
  • KfH Kuratorium für Dialyse und Nierentransplantation, Neu-Isenburg, Germany.
  • University Heart Center Lübeck, Medical Clinic II (Cardiology-Angiology-Intensive Care Medicine), Lübeck, Germany.
  • Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm.
  • Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Marie Evans, Wolfgang Winkelmayer, An S De Vriese

Zitieren

APA

Schneppe, C., Heine, G. H., Eitel, I., Evans, M., Urbanek, L., Winkelmayer, W., & De Vriese, A. S. (2026). Atrial fibrillation in chronic kidney disease - treatment standard. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag263

Vancouver

Schneppe C, Heine GH, Eitel I, Evans M, Urbanek L, Winkelmayer W, et al. Atrial fibrillation in chronic kidney disease - treatment standard. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag263

BibTeX
@article{Schneppe2026,
  author = {Schneppe, Caroline and Heine, Gunnar H and Eitel, Ingo and Evans, Marie and Urbanek, Lukas and Winkelmayer, Wolfgang and De Vriese, An S},
  title = {Atrial fibrillation in chronic kidney disease - treatment standard},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag263}
}
Kostenlos starten →